Marco Lobba
Co-Founder & Chief Executive Officer CatenaBio
Marco Lobba, Ph.D., is the Co‑Founder and CEO of Catena Bio, where he leads the development of next‑generation site‑specific enzymatic conjugation technologies for advanced ADC and bioconjugate therapeutics. He earned his Ph.D. in Chemistry from UC Berkeley as a joint researcher in the laboratories of Jennifer Doudna and Matt Francis, focusing on innovative bioconjugation strategies and CRISPR delivery. Before founding Catena Bio, Marco served in quality leadership roles at Anresco Laboratories, managing ISO 17025 compliance, FDA audit response, and R&D initiatives. His background spans surface chemistry, protein interactions, and translational bioconjugation, bringing deep technical and operational expertise to the field.
Seminars
As tumor heterogeneity and acquired resistance continue to limit the durability of single-payload ADCs, dual-payload
strategies are emerging as a powerful approach to deliver complementary mechanisms of action within a single, precisely engineered construct.
Join leading experts as they discuss how orthogonal chemistry, enzymatic precision, and innovative linker design can converge to create stable, scalable, and clinically translatable dual-payload ADC platforms by:
- Balancing combinatorial potency with molecular precision, examining how one-step multi-payload conjugation, glycan directed strategies, and orthogonal enzymatic chemistries can achieve controlled payload ratios and spatial placement to address tumor heterogeneity without compromising stability
- Redefining site-specific conjugation as the foundation for dual-payload success, debating how high-precision enzymatic platforms and EGCit-enabled linker systems can deliver homogeneous constructs with optimized DAR distribution, improved pharmacokinetics, and reduced off-target toxicity
- Designing linker architectures to strategically combat resistance, evaluating how innovative cleavable, traceless, or modality-specific linkers can coordinate sequential or complementary payload release, integrate novel payload classes, and maintain manufacturability while expanding the therapeutic index
- Mitigating systemic toxicity through highly stable, site‑specific enzymatic conjugation that maintains linker integrity and minimizes premature payload release
- Enhancing anti‑tumor activity with hydrophilic, next‑generation linker architectures designed to improve solubility, reduce aggregation, and support dual‑payload loading
- Streamlining bioconjugation workflows with modular, enzyme‑driven manufacturing that enables reproducible DAR control, orthogonality, and scalability for complex ADC formats
